Home The $10 Billion Reason That This Tiny Biotech Stock Could Soar
 

Keywords :   


The $10 Billion Reason That This Tiny Biotech Stock Could Soar

2015-02-22 17:00:08| Biotech - Topix.net

If Portola can demonstrate that betrixaban can control bleeding in hospital and post-discharge patients, it could become a big player in the $10 billion market for anticoagulants. Displacing a long-standing leader Warfarin has been used for decades by doctors to help keep blood flowing freely in heart disease and post-operative patients.

Tags: stock reason billion tiny

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news

»
05.11PM responds to Sir Alan Bates after repeated requests
05.11American Angus elects 2024-25 board leaders
05.11Atlantic Tropical Weather Outlook
05.11Eastern North Pacific Tropical Weather Outlook
05.11Tropical Storm Rafael Graphics
05.11Tropical Storm Rafael Public Advisory Number 8A
05.11Summary for Tropical Storm Rafael (AT3/AL182024)
05.11Brazil gives green light to medicinal use of Cannabis in animals
More »